Woodward, Gary;
Bajre, Mamta;
Bhattacharyya, Sanjeev;
Breen, Maria;
Chiocchia, Virginia;
Dawes, Helen;
Debhi, Hakim-Moulay;
... Leeson, Paul; + view all
(2023)
PROTEUS Study: A Prospective Randomised Controlled Trial Evaluating the Use of Artificial Intelligence in Stress Echocardiography.
American Heart Journal
10.1016/j.ahj.2023.05.003.
(In press).
![[thumbnail of Frangou_A Prospective Randomised Controlled Trial Evaluating the Use of Artificial Intelligence in Stress Echocardiography_Pre-proof.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Frangou_A Prospective Randomised Controlled Trial Evaluating the Use of Artificial Intelligence in Stress Echocardiography_Pre-proof.pdf - Accepted Version Access restricted to UCL open access staff until 15 May 2024. Download (1MB) |
Abstract
BACKGROUND: Stress echocardiography (SE) is one of the most commonly used diagnostic imaging tests for coronary artery disease (CAD) but requires clinicians to visually assess scans to identify patients who may benefit from invasive investigation and treatment. EchoGo Pro provides an automated interpretation of SE based on artificial intelligence (AI) image analysis. In reader studies, use of EchoGo Pro when making clinical decisions improves diagnostic accuracy and confidence. Prospective evaluation in real world practice is now important to understand the impact of EchoGo Pro on the patient pathway and outcome. METHODS/DESIGN: PROTEUS is a randomised, multicentre, two-armed, non-inferiority study aiming to recruit 2,500 participants from National Health Service (NHS) hospitals in the UK referred to SE clinics for investigation of suspected CAD. All participants will undergo a stress echocardiogram protocol as per local hospital policy. Participants will be randomised 1:1 to a control group, representing current practice, or an intervention group, in which clinicians will receive an AI image analysis report (EchoGo Pro, Ultromics Ltd, Oxford, UK) to use during image interpretation, indicating the likelihood of severe CAD. The primary outcome will be appropriateness of clinician decision to refer for coronary angiography. Secondary outcomes will assess other health impacts including appropriate use of other clinical management approaches, impact on variability in decision making, patient and clinician qualitative experience and a health economic analysis. DISCUSSION: This will be the first study to assess the impact of introducing an AI medical diagnostic aid into the standard care pathway of patients with suspected CAD being investigated with SE.
| Type: | Article |
|---|---|
| Title: | PROTEUS Study: A Prospective Randomised Controlled Trial Evaluating the Use of Artificial Intelligence in Stress Echocardiography |
| Location: | United States |
| DOI: | 10.1016/j.ahj.2023.05.003 |
| Publisher version: | http://doi.org/10.1016/j.ahj.2023.05.003 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Artificial Intelligence, Cardiac Imaging, Cardiovascular Health, Coronary Angiography, Coronary Artery Disease, Stress Echocardiography |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10170526 |
Archive Staff Only
 |
View Item |
